Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects

Martin S Weber; Til Menge; Klaus Lehmann-Horn; Helena C Kronsbein; Uwe Zettl; Johann Sellner; Bernhard Hemmer; Olaf Stüve

Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects

Martin S Weber, Til Menge, Klaus Lehmann-Horn, Helena C Kronsbein, Uwe Zettl, Johann Sellner (Co-author), Bernhard Hemmer, Olaf Stüve

Department of Neurology

Research output: Contribution to journal › Review article › peer-review

43 Citations (Web of Science)

Original language	English
Pages (from-to)	209-219
Journal	CURRENT PHARMACEUTICAL DESIGN
Volume	18
Issue number	2
Publication status	Published - 2012

Keywords

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
PLACEBO-CONTROLLED TRIAL
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS
CEREBRAL PERIVASCULAR SPACES
B-CELL DEPLETION
TERM-FOLLOW-UP
GLATIRAMER ACETATE
DOUBLE-BLIND
DENDRITIC CELLS
MULTICENTER TRIAL

Cite this

Weber, M. S., Menge, T., Lehmann-Horn, K., Kronsbein, H. C., Zettl, U., Sellner, J., Hemmer, B., & Stüve, O. (2012). Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. CURRENT PHARMACEUTICAL DESIGN , 18(2), 209-219.

Weber, Martin S ; Menge, Til ; Lehmann-Horn, Klaus et al. / Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. In: CURRENT PHARMACEUTICAL DESIGN 2012 ; Vol. 18, No. 2. pp. 209-219.

@article{9be6d4310efd411e80c755c091f7a858,

title = "Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects",

keywords = "PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, PLACEBO-CONTROLLED TRIAL, EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS, CEREBRAL PERIVASCULAR SPACES, B-CELL DEPLETION, TERM-FOLLOW-UP, GLATIRAMER ACETATE, DOUBLE-BLIND, DENDRITIC CELLS, MULTICENTER TRIAL",

author = "Weber, \{Martin S\} and Til Menge and Klaus Lehmann-Horn and Kronsbein, \{Helena C\} and Uwe Zettl and Johann Sellner and Bernhard Hemmer and Olaf St{\"u}ve",

note = "Weber, MS [1] ; Menge, T [2] ; Lehmann-Horn, K [1] ; Kronsbein, HC [1] ; Zettl, U [3] ; Sellner, J [1,4] ; Hemmer, B [1] ; Stuve, O [5,6,7] [ 1 ] Tech Univ Munich, Dept Neurol, D-81675 Munich, Germany [ 2 ] Univ Dusseldorf, Dept Neurol, Fac Med, Dusseldorf, Germany [ 3 ] Univ Rostock, Dept Neurol, D-2500 Rostock 1, Germany [ 4 ] Paracelsus Med Univ, Dept Neurol, Christian Doppler Klin, Salzburg, Austria [ 5 ] VA N Texas Hlth Care Syst, Med Serv, Neurol Sect, Dallas, TX USA [ 6 ] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA [ 7 ] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA",

year = "2012",

language = "English",

volume = "18",

pages = "209--219",

journal = "CURRENT PHARMACEUTICAL DESIGN ",

issn = "1381-6128",

number = "2",

}

Weber, MS, Menge, T, Lehmann-Horn, K, Kronsbein, HC, Zettl, U, Sellner, J, Hemmer, B & Stüve, O 2012, 'Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects', CURRENT PHARMACEUTICAL DESIGN , vol. 18, no. 2, pp. 209-219.

Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. / Weber, Martin S; Menge, Til; Lehmann-Horn, Klaus et al.
In: CURRENT PHARMACEUTICAL DESIGN , Vol. 18, No. 2, 2012, p. 209-219.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects

AU - Weber, Martin S

AU - Menge, Til

AU - Lehmann-Horn, Klaus

AU - Kronsbein, Helena C

AU - Zettl, Uwe

AU - Sellner, Johann

AU - Hemmer, Bernhard

AU - Stüve, Olaf

N1 - Weber, MS [1] ; Menge, T [2] ; Lehmann-Horn, K [1] ; Kronsbein, HC [1] ; Zettl, U [3] ; Sellner, J [1,4] ; Hemmer, B [1] ; Stuve, O [5,6,7] [ 1 ] Tech Univ Munich, Dept Neurol, D-81675 Munich, Germany [ 2 ] Univ Dusseldorf, Dept Neurol, Fac Med, Dusseldorf, Germany [ 3 ] Univ Rostock, Dept Neurol, D-2500 Rostock 1, Germany [ 4 ] Paracelsus Med Univ, Dept Neurol, Christian Doppler Klin, Salzburg, Austria [ 5 ] VA N Texas Hlth Care Syst, Med Serv, Neurol Sect, Dallas, TX USA [ 6 ] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA [ 7 ] Univ Texas SW Med Ctr Dallas, Dept Immunol, Dallas, TX 75390 USA

PY - 2012

Y1 - 2012

KW - PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

KW - PLACEBO-CONTROLLED TRIAL

KW - EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS

KW - CEREBRAL PERIVASCULAR SPACES

KW - B-CELL DEPLETION

KW - TERM-FOLLOW-UP

KW - GLATIRAMER ACETATE

KW - DOUBLE-BLIND

KW - DENDRITIC CELLS

KW - MULTICENTER TRIAL

M3 - Review article

C2 - 22229582

SN - 1381-6128

VL - 18

SP - 209

EP - 219

JO - CURRENT PHARMACEUTICAL DESIGN

JF - CURRENT PHARMACEUTICAL DESIGN

IS - 2

ER -

Weber MS, Menge T, Lehmann-Horn K, Kronsbein HC, Zettl U, Sellner J et al. Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects. CURRENT PHARMACEUTICAL DESIGN . 2012;18(2):209-219.